Guggenheim Capital LLC Incyte Corp Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Incyte Corp stock. As of the latest transaction made, Guggenheim Capital LLC holds 76,058 shares of INCY stock, worth $5.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

76,058

Previous 42,497 78.97%

Holding current value

$5.4 Million

Previous $2.58 Million 95.15%

% of portfolio

0.04%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$57.33 - $68.61 $1.92 Million - $2.3 Million	33,561 Added 78.97%	76,058 $5.03 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $2.52 Million - $3.13 Million	-49,161 Reduced 53.64%	42,497 $2.58 Million
Q1 2024 May 14, 2024	SELL	$56.55 - $66.59 $804,536 - $947,375	-14,227 Reduced 13.44%	91,658 $5.22 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $1.3 Million - $1.6 Million	-24,894 Reduced 19.04%	105,885 $6.65 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $1.02 Million - $1.16 Million	-17,586 Reduced 11.85%	130,779 $7.56 Million
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $2.48 Million - $3.07 Million	40,657 Added 37.75%	148,365 $9.24 Million
Q1 2023 May 10, 2023	BUY	$70.23 - $86.01 $322,917 - $395,473	4,598 Added 4.46%	107,708 $7.78 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $1.65 Million - $2.07 Million	24,572 Added 31.29%	103,110 $8.28 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $936,248 - $1.17 Million	-14,147 Reduced 15.26%	78,538 $5.23 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $2.58 Million - $3.25 Million	-39,031 Reduced 29.63%	92,685 $7.04 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $309,963 - $374,238	4,695 Added 3.7%	131,716 $10.5 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $3.24 Million - $3.79 Million	-51,119 Reduced 28.7%	127,021 $9.32 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $5,356 - $6,553	-78 Reduced 0.04%	178,140 $12.3 Million
Q2 2021 Aug 13, 2021	BUY	$79.87 - $87.53 $1.1 Million - $1.21 Million	13,802 Added 8.39%	178,218 $15 Million
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $616,294 - $814,753	-8,107 Reduced 4.7%	164,416 $13.4 Million
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $391,185 - $473,356	-4,845 Reduced 2.73%	172,523 $15 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $2.25 Million - $2.9 Million	-26,467 Reduced 12.98%	177,368 $15.9 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $2 Million - $2.94 Million	26,956 Added 15.24%	203,835 $21.2 Million
Q1 2020 Jun 02, 2020	SELL	$63.18 - $85.97 $3.29 Million - $4.47 Million	-52,011 Reduced 22.72%	176,879 $13 Million
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $1.04 Million - $1.36 Million	14,238 Added 6.63%	228,890 $20 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $2.07 Million - $2.46 Million	28,427 Added 15.26%	214,652 $15.9 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $796,148 - $960,532	-10,829 Reduced 5.5%	186,225 $15.8 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $756,491 - $1.05 Million	11,902 Added 6.43%	197,054 $16.9 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $1.18 Million - $1.41 Million	-20,227 Reduced 9.85%	185,152 $11.8 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $702,900 - $844,960	11,383 Added 5.87%	205,379 $14.2 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $32.3 Million - $44.5 Million	-530,150 Reduced 73.21%	193,996 $13 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $943,893 - $1.15 Million	-11,364 Reduced 1.55%	724,146 $60.3 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $9.96 Million - $12.4 Million	106,468 Added 16.93%	735,510 $69.7 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $68.7 Million - $87 Million	629,042	629,042 $73.4 Million

Others Institutions Holding INCY

# of Institutions

642

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Incyte Corp Transaction History